Liver International

• Risk of Hepatic and Extrahepatic Cancer in NAFLD This study investigated the risk of hepatic and extrahepatic cancer in patients with NAFLD compared to the general population.
  Liver International, May 16, 2022
• Adherence to the DASH Diet and NAFLD Is the DASH (Dietary Approaches to Stop Hypertension) diet effective at lowering risk of NAFLD?
  Liver International, May 09, 2022
• Alcohol-related Hepatitis in the First Months of COVID-19 This study investigated the impact of the COVID-19 pandemic on alcohol-related liver disease in the summer of 2020 compared with the same period in 2016-2019.
  Liver International, May 02, 2022
• Incidence of HCV Related HCC in the Era of IFN-free Therapies This study examined trends over time of HCV-associated hepatocellular carcinoma. How has incidence changed since the introduction of IFN-free therapies?
  Liver International, April 25, 2022
• Immunosuppressive Drugs and COVID-19 Severity in AIH This study found that patients with autoimmune hepatitis who were taking certain immunosuppressants prior to the onset of COVID-19 had more severe courses of COVID-19.
  Liver International, April 11, 2022
• Assessing Liver Steatosis in the Obese Before Bariatric Surgery Is the ultrasound-based controlled attenuation parameter accurate for grading liver steatosis among individuals with morbid obesity before and after bariatric surgery?
  Liver International, April 04, 2022
• Glycosylated 4-methylumbelliferone as Targeted Therapy for HCC This study found that glycosylation of 4MUR can improve its selectivity to tumor cells and may potentially be an effective targeted therapy for hepatocellular carcinoma.
  Liver International, March 28, 2022
• Long-Term Prognosis in Alcohol-related Liver Disease or NAFLD Metabolic syndrome and alcohol use frequently co-exist. This study assessed survival in patients with NAFLD according to alcohol use and ALD according to the presence of metabolic syndrome.
  Liver International, March 21, 2022
• Epidemiological and Clinical Features of MAFLD and NAFLD The transition from the nomenclature NAFLD to MAFLD remains heavily debated. How do their epidemiological and clinical features compare, and is MAFLD the preferable terminology?
  Liver International, March 14, 2022
• Novel Quantitative Ultrasound Technique for Identifying NASH The authors developed and validated a non-invasive tool based on quantitative ultrasound which provides a practical way of identifying the presence of NASH with and without early fibrosis.
  Liver International, March 07, 2022
• HCV Care: Targeting People With Diabetes, Hazardous Alcohol Use What factors drive late presentation for HCV care? This study highlights the need to identify and target people with diabetes and/or past or current hazardous alcohol use for HCV screening.
  Liver International, February 28, 2022
• Binge Drinking and Fibrogenesis: More Than Just a Hangover A new study linking binge drinking and the potential for fibrogenesis suggests that the consequences of binge drinking may extend far beyond just a hangover.
  Liver International, February 21, 2022
• Binge Drinking Induces Markers of Hepatic Fibrogenesis This study investigated the effects on hepatic extracellular matrix turnover following a binge drinking episode.
  Liver International, February 14, 2022
• Waist and Hip Circumference and Risk of Liver Disease Prior studies have shown that high values of waist-hip ratio are risk factors for severe liver disease. Do waist and hip circumference each exhibit independent associations with risk of liver disease?
  Liver International, February 07, 2022
• Association Between Circulating Bile Acid Alterations and NASH This study aimed to elucidate alterations in bile acid metabolism according to NAFLD severity, in the absence of obesity.
  Liver International, January 31, 2022
• Impact of COVID-19-related Public Health Measures on HCV Testing What impact did public health measures introduced to limit transmission of SARS-CoV-2 have on HCV testing and the HCV care cascade?
  Liver International, January 24, 2022
• HCC Risk in Hepatitis C Stage-3 Fibrosis After SVR With DAAs Do patients with chronic hepatitis C and stage 3 fibrosis remain at risk of hepatocellular carcinoma even after sustained virological response with DAAs?
  Liver International, January 17, 2022
• Peripheral Neuropathy After Viral Eradication in Chronic HCV Chronic HCV infection can lead to extra-hepatic complications including peripheral neuropathy. Does HCV eradication achieved by DAAs impact the course of HCV-related neuropathy?
  Liver International, December 13, 2021
• COVID-19 and Metabolic-associated Liver Disease How, and by what mechanisms, does MALD impact outcomes in patients with COVID-19? This review aims to elucidate the complex pathophysiological relationship of MALD and COVID-19.
  Liver International, December 06, 2021
• High Prevalence of Celiac Disease in Autoimmune Hepatitis Do individuals with autoimmune hepatitis demonstrate a higher prevalence of celiac disease compared to the general population?
  Liver International, November 29, 2021